: iStockAnalyst.com Symbols Feed

Emerging Biotech & Pharma Index: 36 More Cos.

Mon, 24 Nov 2008 05:35:00 GMT

The accompanying table (click to enlarge or download) includes the 36 remaining companies in the ETF Innovators (ETFI) Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff. However, several of the companies included in the remaining group of 36 have been in the news recently due to [More...]

Updated FDA Calendar Of 73 Decision Dates

Sat, 22 Nov 2008 16:52:00 GMT

The accompanying table (click to enlarge or download) includes an updated calendar of 75 expected FDA decision dates as part of the ETF Innovators (ETFI) New Drug Regulatory Catalyst Index, which includes a full slate of expected action before year-end outlined in my previous article. The last few days have been busy for antibiotics at the agency, resulting in sharply lower stock prices for Targanta Therapeutics (TARG) and Theravance (THRX). An FDA panel voted against Targanta's oritavancin, which has an upcoming decision in early December and sent shares crashing from 8 bucks before[More...]

A Backlog Of Decisions Is Building At The FDA

Fri, 07 Nov 2008 15:43:00 GMT

The accompanying table presents 70 FDA product approval decision dates along with the market caps and one year stock price change for the underlying companies. A note of caution for investors and traders is that the most common outcome from the FDA in the past year has been a delay in decisions due to understaffed conditions at the agency. However, several companies have pending decisions which are likely to occur either before year-end or early next year and will have a major impact on their stock prices. Discovery Labs (DSCO) submitted its complete response to the FDA in response to a May approvable letter for Surfaxin three weeks ago on 10/17 and had expected the agency to respond last week on the[More...]

FDA Stings Pharma Big and Small

Mon, 23 Jun 2008 15:57:23 GMT

The first shock came after Merck (MRK) and Schering-Plough’s (SGP) Vytorin ENHANCE study. Surrogate markers like cholesterol counts would no longer be enough to garner marketing approval.[More...]

NASDAQ Technical Picture - Expansion

Fri, 02 May 2008 05:56:25 GMT

The only thi[More...]

NASDAQ Technical Picture - Lower Trendline Holding

Thu, 21 Feb 2008 12:48:43 GMT

The NASDAQ dropped in opening trade due to higher than expected CPI inflation data. Both the Nasdaq Comp an[More...]

Neurogen Corp. reports $1.9M loss, sells real estate

Sat, 07 Nov 2009 16:46:00 GMT

Nov. 7--BRANFORD -- Neurogen Corp., which is being acquired by a San Diego company in a deal that will close its local operations, on Friday reported its latest financial earnings and said it has sold its headquarters at 45 N.E. Industrial Road to a commercial real estate developer.
The company, founded in 1987, announced in August it would be acquired by Ligand Pharmaceuticals Inc., a California company that will not maintain a presence in town.
The deal is expected to close this quarter.

: iStockAnalyst.com Symbols Feed

Emerging Biotech & Pharma Index: 36 More Cos.

Updated FDA Calendar Of 73 Decision Dates

A Backlog Of Decisions Is Building At The FDA

FDA Stings Pharma Big and Small

NASDAQ Technical Picture - Expansion

NASDAQ Technical Picture - Lower Trendline Holding

Neurogen Corp. reports $1.9M loss, sells real estate

Movers: GE, Nike, Discover Financial, Capital One, Goodyear

Ligand to Acquire Metabasis for Cash and Contingent Value Rights

Ligand Terminates Long-Term Lease Obligation

Ligand Pharmaceuticals Announces Second Quarter Results

Ligand and Organon Mutually Terminate Collaboration and License Agreement

Ligand to Hold Second Quarter Results Conference Call on August 3

Ligand Licenses Patents for Desulfated Heparin Technology to ParinGenix

Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders

CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results

Ligand Pharmaceuticals Announces First Quarter Results

Ligand to Hold First Quarter Results Conference Call on May 6

Form 4 LAMPERT MARK N For: Aug 24 (10K)

Form 4 LAMPERT MARK N For: Jun 25 (10K)

Form 4/A KNOTT DAVID M For: Feb 17 (10K)

Form 4/A KNOTT DAVID M For: Apr 07 (10K)

Form 4 KNOTT DAVID M For: Apr 07 (10K)

Form 4 Dziewanowska Zofia E For: Feb 25 (10K)

Form 4 KNOTT DAVID M For: Feb 17 (10K)

Form 4 Kazmi Syed For: Feb 23 (10K)

Form 4 Berkman Charles S For: Feb 23 (10K)

Form 4 Sharp John P For: Feb 23 (10K)